

REMARKS

At the outset, Applicants wish to thank the Examiner for the courtesies extended during the June 13, 2007 telephone interview. At that interview, possible amendments to put the claims in allowable form were discussed. Applicants also wish to thank the Examiner for indicating that claims 1, 2, 5-7, 11 and 12 are allowed, and that claim 10 would be allowable if rewritten in independent form including all of the limitations of the base claim and intervening claims.

Claims 1-12 are pending in this application. By this amendment, claims 3 and 4 have been cancelled without prejudice or disclaimer. Claim 10 has been rewritten in independent form, and claim 9 has been amended to recite the biscyclopentadienyl ligand system of claim 10.

Finally, the Abstract has been amended to address the Examiner's objection as being too long. This amendment to the specification does not include new matter.

Objection to the Specification

The Examiner has objected to the Abstract for allegedly being too lengthy. Appropriate correction has been made. Reconsideration and withdrawal of the Objection respectfully is requested.

Claim Rejections

Rejections under 35 USC §103

- A. Response to rejection of claims 3, 4, and 9 under 35 U.S.C. §103(a) as being unpatentable over Küber.


In response to the rejection of claims 3, 4, and 9 under 35 U.S.C. §103(a) as being unpatentable over U.S. Patent No. 5,840,947 of Küber et al. ("Küber"), Applicants have cancelled claims 3 and 4, thereby rendering the rejection relative to these claims moot. With respect to claim 9, Applicants have amended claim 9 to recite the biscyclopentadienyl ligand system of claim 10. Inasmuch as the Examiner has indicated that claim 10 would be allowable if

rewritten in independent form including all the limitations of the base claim and any intervening claims, Applicants respectfully submit that claim 9 now stands in condition for allowance.

Reconsideration and withdrawal of the rejection is respectfully requested.


The Commissioner is hereby authorized to charge U.S. PTO Deposit Account 08-2336 in the amount of any fee required for consideration of this Amendment.

Respectfully submitted,



William R. Reid
Registration No. 47,894
Attorney for Applicant

I hereby certify that this correspondence is being deposited with sufficient postage thereon with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 21, 2007.


June 21 2007

Date of Signature

Basell USA Inc.
912 Appleton Road
Elkton, MD 21921
Attorney's Telephone No.: 410-996-1783
Attorney's Fax No.: 410-996-1560